MFN

Market Access

Blue and white pills in pharma manufacturing line

Pharma’s most expensive question is the last one asked

Whether a drug can secure reimbursement is pharma's billion-dollar question, and the companies that succeed will be those that answer it sooner.

News

White House signs pricing deals with nine more pharmas

Nine mid-sized pharmas have signed up for the Trump administration's Most-Favoured Nation (MFN) pricing deals, pledging almost $20bn in investments.

Market Access

The new commercialisation playbook: What BIO 2026 taught eme...

BIO International focused on how emerging biotech companies should approach their first product launch outside the United States, typically in Europe.

News

MFN affecting Swiss medicines access, says Interpharma

Pharma groups have held back from submitting around a third of their new medicines for reimbursement in Switzerland, impeding patient access.

Oncology

How IRA, MFN, and HTA are rewriting oncology launch strategy...

Market Access

Pharma’s most expensive question is the last one asked

White House signs pricing deals with nine more pharmas

The new commercialisation playbook: What BIO 2026 taught eme...

MFN affecting Swiss medicines access, says Interpharma

How IRA, MFN, and HTA are rewriting oncology launch strategy...

MFN and TrumpRx: What’s the real impact for the American con...

Hengrui gets world-first okay for platelet drug hetrombopag

Discover a new era of healthcare panel engagement: Grounded ...

MFN

Editor's Picks